William, BM, de Lima, M. Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies. Drugs & Aging. 2013;30(6):373–81.CrossRefGoogle ScholarPubMed

Hourigan, CS, McCarthy, P, de Lima, M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(2):154–63.Google Scholar

de Lima, M, Porter, DL, Battiwalla, M, Bishop, MR, Giralt, SA, Hardy, NM, et al. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(1):4–13.Google Scholar

Gisselbrecht, C, Schmitz, N, Mounier, N, Singh Gill, D, Linch, DC, Trneny, M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(36):4462–9.CrossRefGoogle Scholar

Goldman, JM, Gale, RP. What does MRD in leukemia really mean? Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2014;28(5):1131.CrossRefGoogle ScholarPubMed

Hourigan, CS. Next Generation MRD. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(9):1259–60.CrossRefGoogle ScholarPubMed

Puig, N, Sarasquete, ME, Balanzategui, A, Martinez, J, Paiva, B, Garcia, H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391–7.CrossRefGoogle ScholarPubMed

Bruggemann, M, Raff, T, Kneba, M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012;120(23):4470–81.Google Scholar

Richardson, SE, Khan, I, Rawstron, A, Sudak, J, Edwards, N, Verfuerth, S, et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. British Journal of Haematology. 2013;160(5):640–8.CrossRefGoogle ScholarPubMed

Pott, C, Bruggemann, M, Ritgen, M, van der Velden, VH, van Dongen, JJ, Kneba, M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods in Molecular Biology (Clifton, NJ). 2013;971:175–200.CrossRefGoogle ScholarPubMed

Gimenez, E, Chauvet, M, Rabin, L, Puteaud, I, Duley, S, Hamaidia, S, et al. Cloned IGH VDJ targets as tools for personalized minimal residual disease monitoring in mature lymphoid malignancies; a feasibility study in mantle cell lymphoma by the Groupe Ouest Est d’Etude des Leucemies et Autres Maladies du Sang. British Journal of Haematology. 2012;158(2):186–97.Google Scholar

Radich, JP. Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network. 2013;11(5 Suppl):663–6.CrossRefGoogle ScholarPubMed

O’Donnell, MR, Tallman, MS, Abboud, CN, Altman, JK, Appelbaum, FR, Arber, DA, et al. Acute myeloid leukemia, version 2.2013. Journal of the National Comprehensive Cancer Network. 2013;11(9):1047–55.Google Scholar

Hourigan, CS, Karp, JE. Minimal residual disease in acute myeloid leukaemia. Nature Reviews Clinical Oncology. 2013;10(8):460–71.Google Scholar

Qin, YZ, Zhu, HH, Liu, YR, Wang, YZ, Shi, HX, Lai, YY, et al. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes. Leukemia & Lymphoma. 2013;54(7):1442–9.Google Scholar

Grimwade, D, Freeman, SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “Prime Time”? Blood. 2014;124(23):3345–55.Google Scholar

Logan, AC, Vashi, N, Faham, M, Carlton, V, Kong, K, Buno, I, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2014;20(9):1307–13.Google Scholar

Brenner, MK, Rill, DR, Moen, RC, Krance, RA, Mirro, J Jr., Anderson, WF, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341(8837):85–6.CrossRefGoogle ScholarPubMed

Stewart, AK, Vescio, R, Schiller, G, Ballester, O, Noga, S, Rugo, H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001;19(17):3771–9.CrossRefGoogle ScholarPubMed

Schouten, HC, Qian, W, Kvaloy, S, Porcellini, A, Hagberg, H, Johnsen, HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;21(21):3918–27.CrossRefGoogle ScholarPubMed

Furman, RR, Grossbard, ML, Johnson, JL, Pecora, AL, Cassileth, PA, Jung, SH, et al. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia & Lymphoma. 2011; 52(4):587–96.Google Scholar

Pettengell, R, Schmitz, N, Gisselbrecht, C, Smith, G, Patton, WN, Metzner, B, et al. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(13):1624–30.CrossRefGoogle ScholarPubMed

Wetzler, M, Watson, D, Stock, W, Koval, G, Mulkey, FA, Hoke, EE, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99(1):111–5.CrossRefGoogle ScholarPubMed

Younes, A, Bartlett, NL, Leonard, JP, Kennedy, DA, Lynch, CM, Sievers, EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. The New England Journal of Medicine. 2010;363(19):1812–21.Google Scholar

Rytting, M, Triche, L, Thomas, D, O’Brien, S, Kantarjian, H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer. 2014;61(2):369–72.Google Scholar

O’Hear, C, Inaba, H, Pounds, S, Shi, L, Dahl, G, Bowman, WP, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer. 2013;119(22):4036–43.Google Scholar

de Lima, M, Giralt, S, Thall, PF, de Padua, Silva L, Jones, RB, Komanduri, K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420–31.CrossRefGoogle ScholarPubMed

Choi, J, Ritchey, J, Prior, JL, Holt, M, Shannon, WD, Deych, E, et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116(1):129–39.Google Scholar

Sanchez-Abarca, LI, Gutierrez-Cosio, S, Santamaria, C, Caballero-Velazquez, T, Blanco, B, Herrero-Sanchez, C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115(1):107–21.CrossRefGoogle ScholarPubMed

Goodyear, OC, Dennis, M, Jilani, NY, Loke, J, Siddique, S, Ryan, G, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361–9.Google Scholar

Garcia-Manero, G, Gore, SD, Cogle, C, Ward, R, Shi, T, Macbeth, KJ, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(18):2521–7.Google Scholar

Burchert, A, Nicolaus, K, Huenecke, S, Duenzinger, U, Wolf, A, Bader, P, et al. Post-transplant maintenance with the deacetylase inhibitor panobinostat in patients with high-risk AML or MDS: results of the phase I part of the panobest trial. Blood. 2013;122(21):3315.Google Scholar

Dhedin, N, Huynh, A, Maury, S, Tabrizi, R, Beldjord, K, Asnafi, V, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486–96; quiz 586.Google Scholar

Walter, RB, Buckley, SA, Pagel, JM, Wood, BL, Storer, BE, Sandmaier, BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813–21.Google Scholar

Schroeder, T, Czibere, A, Platzbecker, U, Bug, G, Uharek, L, Luft, T, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229–35.Google Scholar

Thompson, JA, Fisher, RI, Leblanc, M, Forman, SJ, Press, OW, Unger, JM, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood. 2008;111(8):4048–54.Google Scholar

Bolanos-Meade, J, Garrett-Mayer, E, Luznik, L, Anders, V, Webb, J, Fuchs, EJ, et al. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2007;13(10):1185–91.Google Scholar

Simonsson, B, Totterman, T, Hokland, P, Lauria, F, Carella, AM, Fernandez, MN, et al. Roquinimex (Linomide) vs placebo in AML after autologous bone marrow transplantation. Bone Marrow Transplant. 2000;25(11):1121–7.Google Scholar

Attal, M, Harousseau, JL, Leyvraz, S, Doyen, C, Hulin, C, Benboubker, L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289–94.CrossRefGoogle ScholarPubMed

Barlogie, B, Pineda-Roman, M, van Rhee, F, Haessler, J, Anaissie, E, Hollmig, K, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112(8):3115–21.Google Scholar

Lokhorst, HM, van der Holt, B, Zweegman, S, Vellenga, E, Croockewit, S, van Oers, MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010;115(6):1113–20.CrossRefGoogle ScholarPubMed

Morgan, GJ, Davies, FE, Gregory, WM, Bell, SE, Szubert, AJ, Cook, G, et al. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res. 2013;19(21):6030–8.CrossRefGoogle ScholarPubMed

Spencer, A, Prince, HM, Roberts, AW, Prosser, IW, Bradstock, KF, Coyle, L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2009;27(11):1788–93.Google Scholar

Krishnan, A, Pasquini, MC, Logan, B, Stadtmauer, EA, Vesole, DH, Alyea, E 3rd, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. The Lancet Oncology. 2011;12(13):1195–203.Google Scholar

Maiolino, A, Hungria, VT, Garnica, M, Oliveira-Duarte, G, Oliveira, LC, Mercante, DR, et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol. 2012;87(10):948–52.Google Scholar

Stewart, AK, Trudel, S, Bahlis, NJ, White, D, Sabry, W, Belch, A, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 2013;121(9):1517–23.CrossRefGoogle ScholarPubMed

McCarthy, PL, Owzar, K, Hofmeister, CC, Hurd, DD, Hassoun, H, Richardson, PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. The New England Journal of Medicine. 2012;366(19):1770–81.Google Scholar

Attal, M, Lauwers-Cances, V, Marit, G, Caillot, D, Moreau, P, Facon, T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. The New England Journal of Medicine. 2012;366(19):1782–91.CrossRefGoogle ScholarPubMed

Boccadoro, M, Cavallo, F., Gay, F. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. Journal of Clinical Oncology. 2013;(Suppl): Abstract 8509.Google Scholar

Sonneveld, P, Schmidt-Wolf, IG, van der Holt, B, El Jarari, L, Bertsch, U, Salwender, H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(24):2946–55.CrossRefGoogle ScholarPubMed

Cavo, M, Pantani, L, Petrucci, MT, Patriarca, F, Zamagni, E, Donnarumma, D, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9–19.Google Scholar

Mellqvist, UH, Gimsing, P, Hjertner, O, Lenhoff, S, Laane, E, Remes, K, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121(23):4647–54.CrossRefGoogle Scholar

Palumbo, A, Cavallo, F, Gay, F, Di Raimondo, F, Ben Yehuda, D, Petrucci, MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. The New England Journal of Medicine. 2014;371(10):895–905.Google Scholar

Cheson, BD, Bennett, JM, Kopecky, KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–9.Google Scholar

Freireich, EJ, Gehan, EA, Sulman, D, et al. The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 1961;14:593–608.Google Scholar

Bradstock, KF, Janossy, G, Tidman, N, et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukemia. Leuk Res 1981;5:301–9.Google Scholar

Walter, RB, Kantarjian, HM, Huang, X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol 2010;28:1766–71.Google Scholar

Chen, X, Xie, H, Bohm, C, et al. The relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol 2015;33:1258-64.Google Scholar

Freeman, SD, Virgo, P, Couzens, S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patient with acute myeloid leukemia. J Clin Oncol 2013;31:4123–31.Google Scholar

Kang, H, Chen, I-M, Wilson, CS, et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk-classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2010;115:1394–405.Google Scholar

Yang, JJ, Cheng, C, Devidas, M, et al. Genome-wide association study identifies Germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012;120:4197–204.Google Scholar

Beldjord, K, Chevret, S, Asnafi, V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 2014;123:3739–49.Google Scholar

Vora, A, Frost, L, Goodeve, A, et al. Late relapsing childhood lymphoblastic leukemia. Blood 1998;92:2334–7.Google Scholar

Ommen, HB, Schnittger, S, Jovanovic, JV, et al. Strikingly different molecular relapse Grimwadekinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010;115:198–205.Google Scholar

Parker, C, Waters, R, Leighton, C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukemia (ALL R3): an open-label randomized trial. The Lancet 2010;376:2009–17.Google Scholar

Butturini, A, Klein, J, Gale, RP. Modeling minimal residual disease (MRD)-testing. Leuk Res 2003;27:293–300.Google Scholar

Mullighan, CG, Su, X, Zhang, J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360:470–80.Google Scholar

van der Veer, A, Waanders, E, Pieters, R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013;122:2622–9.CrossRefGoogle Scholar

Roberts, KG, Li, Y, Payne-Turner, D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014;371:1005–15.CrossRefGoogle ScholarPubMed

Lee, S, Kim, D-W, Cho, B-S, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2012;26:2367–74.Google Scholar

Ravandi, F, Jorgensen, JL, Thomas, DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 2013;122:1214–21.Google Scholar

Jeha, S, Coustan-Smith, E, Pei, D, et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2014;120:1514–9.Google Scholar

Helgestad, J, Rosthøj, S, Johansen, P, et al. Bone marrow aspiration technique may have an impact on therapy stratification in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57:224–6.Google Scholar

Paietta, E. Minimal residual disease in AML: coming of age. Hematol Am Soc Hematol Educ Program 2012;2012:35–42.Google Scholar

Paietta, E. Minimal residual disease in acute leukaemia: a guide to precision medicine ready for prime time? In Treatment Strategies Haematology, Vol 4, issue 2, 2014, pp 45-48.Google Scholar

Grimwade, D, Freeman, SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood 2014;124:3345–55.Google Scholar

Loken, MR, Chu, S-C, Fritschle, W, et al. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry Part B (Clin Cytometry) 2009;76B:27–36.Google Scholar

Buccisano, F, Maurillo, L, Del Principe, MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119:332–41.Google Scholar

Loken, MR, Alonzo, TA, Pardo, L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children’s Oncology Group. Blood 2012;120:1581–8.Google Scholar

Inaba, H, Coustan-Smith, E, Cao, X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol 2012;30:3625–32.Google Scholar

Campana, D, Coustan-Smith, E. Measurements of treatment response in childhood acute leukemia. Korean J Hematol 2012;47:245–54.CrossRefGoogle ScholarPubMed

McKenna, RW, Washington, LT, Aquino, DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursor) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001;98:2498–507.CrossRefGoogle Scholar

Sevilla, DW, Colovai, AI, Emmons, FN, et al. Hematogones: a review and update. Leuk Lymphoma 2010;51:10–19.Google Scholar

Sedek, L, Bulsa, J, Sonsala, A, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts? Cytometry B Clin Cytom 2014;86:329–39.Google Scholar

Loken, MR, Alonzo, TA, Pardo, L, et al. Multidimensional flow cytometry significantly improves upon the morphologic assessment of post-induction marrow remission status-comparison of morphology and multidimensional flow cytometry: a report from the Children’s Oncology Group AML Protocol AAML0531. Blood 2012;120(8):1581–8.Google Scholar

Grimwade, D, Tallman, M. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Leuk Research 2011;35:3–7.Google Scholar

Wang, F, Travis, J, DeLaBarre, B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340:622–6.Google Scholar

Gaipa, G, Cazzaniga, G, Valsecchi, MG, et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 2012;97:1582–93.CrossRefGoogle ScholarPubMed

Van der Velden, VHJ, Cazzaniga, G, Schrauder, A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604–11.CrossRefGoogle ScholarPubMed

van Dongen, JJM. EuroFlow Educational Book 2012; Rotterdam: Macmillan.Google Scholar

Boeckx, N, Willemse, MJ, Szczepanski, T, et al. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia 2002;16:368–75.Google Scholar

Warren, EH, Matsen, FA IV, Chou, J. High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology. Blood 2013;122:19–22.Google Scholar

Faham, M, Zheng, J, Moorhead, M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120:5173–80.Google Scholar

Martinez-Lopez, J, Lahuerta, JJ, Pepin, F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123:3073–9.Google Scholar

UK NEQAS. www.ukneqas.org.ukGoogle Scholar

Wood, B. Flow cytometric assessment of MRD. Presented at the FDA Public Workshop on Minimal Residual Disease, FDA White Oak Campus, Silver Spring, MD, April 18, 2012.Google Scholar

Wood, BL. Flow cytometric monitoring of residual disease in acute leukemia. In Czader, M. (ed) Hematological Malignancies: Methods in Molecular Biology, vol 999. 2013; New York: Springer, pp. 123–36.Google Scholar

Chevallier, P, Robillard, N, Ayari, S, et al. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. Br J Haematol 2008;143:744–6.Google Scholar

Chu, PG, Chen, YY, Molina, A, et al. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma 2002;43:2335–41.Google Scholar

Topp, MS, Kufer, P, Gökbuget, N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493–8.Google Scholar

Campana, D. Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? Curr Hematol Malig Rep 2012;7:170–7.CrossRefGoogle ScholarPubMed

van Dongen, JJM, Lhermitte, L, Böttcher, S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908–75.Google Scholar

Zeijlemaker, W, Gratama, JW, Schuurhuis, GJ. Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom 2014;86:3–14.Google Scholar

Coustan-Smith, E, Song, G, Clark, C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011;117:6267–76.Google Scholar

Langebrake, C, Brinkmann, I, Teigler-Schlegel, A, et al. Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring. Cytometry B Clin Cytom 2005;63B:1–9.Google Scholar

Macedo, A, San Miguel, JF, Vidriales, MB, et al. Phenotypic changes in acute myeloid leukemia: implications in the detection of minimal residual disease. J Clin Pathol 1996;49:15–18.Google Scholar

Brϋggemann, M, Raff, T, Kneba, M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012;120:4470–81.Google Scholar

Wu, D, Emerson, RO, Sherwood, A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res 2014;20:4540–8.Google Scholar

Thol, F, Kölking, B, Damm, F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosom Cancer 2012;51:689–95.Google Scholar

Bachas, C, Schuurhuis, GJ, Assaraf, YG, et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012;26:1313–20.Google Scholar

Hou, H-A, Kuo, Y-Y, Liu, C-Y, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012;119:559–68.Google Scholar

Im, AP, Sehgal, AR, Carroll, MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 2014;28:1774–83.Google Scholar

Salipante, SJ, Fromm, JR, Shendure, J, et al. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Mod Pathol 2014;27:1438–46.CrossRefGoogle ScholarPubMed

Stow, P, Key, L, Chen, X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115:4657–63.Google Scholar

Maurillo, L, Buccisano, F, Del Principe, MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;26:4944–51.Google Scholar

Rubnitz, JE, Inaba, H, Dahl, G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. The Lancet 2010;11:543–52.Google Scholar

Terwijn, M, van Putten, WLJ, Kelder, A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013;31:3889–97.Google Scholar

Ganzel, C, Sun, Z, Gönen, M, et al. Minimal residual disease assessment by flow cytometry in AML is an independent prognostic factor even after adjusting for cytogenetic/molecular abnormalities. Blood 2014;124:1016.Google Scholar

Fernandez, HF, Sun, Z, Yao, X, et al. Anthracycline dose intensification in acute myeloid leukemia: Results of ECOG Study E1900. N Engl J Med 2009;361:1249–59.Google Scholar

Perea, G, Lasa, A, Aventin, A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006;20:87–94.Google Scholar

Miyamoto, T, Weissman, IL, Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000;97:7521–6.Google Scholar

Corces-Zimmerman, MR, Hong, W-J, Weissman, IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA 2014;111:2548–53.Google Scholar

Shlush, LI, Zandi, S, Mitchell, A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 2014;506:328–33.Google Scholar

Bodini, M, Ronchini, C, Giacò, L, et al. The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. Blood 2015;125:600–5.Google Scholar

Will, B, Steidl, U. Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. Best Pract Res Clin Haematol 2010;23:391–401.Google Scholar

Ebinger, M, Witte, K-E, Ahlers, J, et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. Leuk Res 2010;34:1139–42.Google Scholar

Terwijn, M, Kelder, A, Snel, AN, et al. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukemia. Int J Lab Hem 2012;34:432–41.Google Scholar

Gerber, JM, Smith, BD, Ngwang, B, et al. A clinically relevant population of leukemic CD34⁺CD38^- cells in acute myeloid leukemia. Blood 2012;119:3571–7.Google Scholar

Roug, AS, Larsen, HØ, Nederby, L, et al. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone – a universal marker combination for the detection of minimal residual disease in acute myeloid leukemia. Br J Haematol 2014;164:212–22.Google Scholar

DiGiuseppe, JA. CD34+/CD38- cells and minimal residual disease in childhood lymphoblastic leukemia. Leuk Res 2010;34:1125–6.Google Scholar

Aoki, Y, Watanabe, T, Saito, Y, et al. Identification of CD34⁺ and CD34^- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood 2014;125:967–80.Google Scholar

Mullighan, CG, Phillips, LA, Su, X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008;322:1377–80.Google Scholar

Notta, F, Mullighan, CG, Wang, JC, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011;469:362–7.Google Scholar

Clappier, E, Gerby, B, Sigaux, F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011;208:653–61.Google Scholar

Klco, JM, Spencer, DH, Miller, CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014;25:379–92.Google Scholar

Inaba, H, Greaves, M, Mullighan, CG. Acute lymphoblastic leukemia. Lancet 2013;381:1943–55.Google Scholar

Chan, SM, Majeti, R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. Int J Hematol 2013;98:648–57.Google Scholar

Peloquin, GL, Chen, YB, Fathi, AT. The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell 2013;4:735–46.Google Scholar

Li, KK, Luo, LF, Shen, Y, et al. DNA methyltransferases in hematologic malignancies. Semin Hematol 2013;50:48–60.Google Scholar

Barreyro, L, Will, B, Bartholdy, B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012;120:1290–8.Google Scholar

Askmyr, M, Ågerstam, H, Hansen, N, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 2013;121:3709–13.Google Scholar

Schultz, KR, Bowman, WP, Aledo, A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children’s Oncology Group study. J Clin Oncol 2009;27:5175–81.CrossRefGoogle ScholarPubMed

Manabe, A, Kawasaki, H, Shimada, H, et al. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph+ALL04. Cancer Med 2015; Jan 31. doi: 10.1002/cam4.383. [Epub ahead of print]Google Scholar

Lee, HJ, Thompson, JE, Wang, ES, Wetzler, M. Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2011;117:1583–94.Google Scholar

Bachanova, V, Marks, DI, Zhang, M-J, et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 2014;28:658–65.Google Scholar

Wetzler, M, Watson, D, Stock, W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica 2014;99:111–5.Google Scholar

Schenk, TM, Keyhani, A, Böttcher, S, et al. Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia 1998;12:666–74.Google Scholar

Rovida, E, Peppicelli, S, Bono, S, et al. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy. Cell Cycle 2014;13:3169–75.Google Scholar

Ribera, J-M. Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma 2013;54:21–7.Google Scholar

Herrmann, H, Sadovnik, I, Cerny-Reiterer, S, et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells in chronic myeloid leukemia. Blood 2014;123:3951–62.Google Scholar

Pfeifer, H, Wassmann, B, Bethge, W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 2013;27:1254–62.Google Scholar

Orgel, E, Tucci, J, Alhushki, W, et al. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood 2014;124:3932–8.Google Scholar

Ehsanipour, EA, Sheng, X, Behan, JW, et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res 2013;73:2998–3006.Google Scholar

Pramanik, R, Sheng, X, Ichihara, B, et al. Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy. Leuk Res 2013;37:503–9.Google Scholar

Borowitz, MJ, Devidas, M, Hunger, SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008;111:5477–85.Google Scholar

Möricke, A, Reiter, A, Zimmermann, M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477–89.Google Scholar

Conter, V, Bartram, CR, Valsecchi, MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206-14.Google Scholar

Corbacioglu, A, Scholl, C, Schlenk, RF, et al. Prognostic impact of miminal residual disease in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol 2010;28:3724–9.Google Scholar

Zhu, H-H, Zhang, X-H, Qin, Y-Z, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood 2013;121:4056–62.Google Scholar

Jourdan, E, Boissel, N, Chevret, S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013;121:2213–23.Google Scholar

Liu Yin, JA, O’Brien, MA, Hills, RK, et al. Minimal residual disease monitoring by RT-qPCR in core-binding factor AML allows risk-stratification and predicts relapse: results of the UK MRC AML-15 trial. Blood 2012;120:2826–35.Google Scholar

Buccisano, F, Maurillo, L, Spagnoli, A, et al. Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia. Blood 2010;116:2295–303.Google Scholar

Gönen, M, Sun, Z, Figueroa, ME, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase III trial, E1900. Blood 2012;120:2297–306.Google Scholar

Waanders, E, van der Velden, VHJ, van der Schoot, CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011;25:254–8.Google Scholar

Geng, H, Brennan, S, Milne, TA, et al. Integrative epigenomic analysis of adult B-acute lymphoblastic leukemia identifies biomarkers and therapeutic targets. Cancer Discovery 2012;2:1004–23.Google Scholar

Kobayashi, CI, Takubo, K, Kobayashi, H, et al. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood 2014;123:2540–9.Google Scholar

Hagedorn, N, Acquaviva, C, Fronkova, E, et al. Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of “isolated” and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. Blood 2007;110:4022–9.Google Scholar

Patel, B, Rai, L, Buck, G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2009;148:80–9.Google Scholar

Grimwade, D, Jovanovic, JV, Hills, RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009;27:3650–8.Google Scholar

Sockel, K, Wermke, M, Radke, J, et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica 2011;96:1568–70.Google Scholar

Platzbecker, U, Wermke, M, Radke, J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012;26:381–9.Google Scholar

Rubnitz, J, Inaba, H, Dahl, G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543–52.Google Scholar

O’Hear, C, Inaba, H, Punds, S, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 2013;119:4036–43.Google Scholar

Annesley, CE, Brown, P. Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol 2015;6:61–79.Google Scholar

Topp, M, Gökbuget, N, Zugmaier, G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185–7.Google Scholar

Goldman, JM, Gale, RP, Horowitz, MM, Biggs, JC, Champlin, RE, Gluckman, E, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108(6):806–14. PubMed PMID: 3285744.Google Scholar

Kolb, HJ, Mittermuller, J, Clemm, C, Holler, E, Ledderose, G, Brehm, G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462–5. PubMed PMID: 2265242.Google Scholar

Dazzi, F, Szydlo, RM, Cross, NC, Craddock, C, Kaeda, J, Kanfer, E, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96(8):2712–6. PubMed PMID: 11023502.Google Scholar

Craddock, C, Szydlo, RM, Klein, JP, Dazzi, F, Olavarria, E, van Rhee, F, et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 2000;96(1):86–90. PubMed PMID: 10891435.Google Scholar

Mackinnon, S, Papadopoulos, EB, Carabasi, MH, Reich, L, Collins, NH, Boulad, F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86(4):1261–8. PubMed PMID: 7632930.Google Scholar

van Rhee, F, Savage, D, Blackwell, J, Orchard, K, Dazzi, F, Lin, F, et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 1998;21(10):1055–61. PubMed PMID: 9632281.Google Scholar

Simula, MP, Marktel, S, Fozza, C, Kaeda, J, Szydlo, RM, Nadal, E, et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia. 2007;21(5):943–8. PubMed PMID: 17361226. Epub 2007/03/16. eng.Google Scholar

Dazzi, F, Szydlo, RM, Craddock, C, Cross, NC, Kaeda, J, Chase, A, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 2000;95(1):67–71. PubMed PMID: 10607686.Google Scholar

Fozza, C, Szydlo, RM, Abdel-Rehim, MM, Nadal, E, Goldman, JM, Apperley, JF, et al. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Bri J Haematol. 2007;136(6):833–6. PubMed PMID: 17341269. Epub 2007/03/08. eng.Google Scholar

Ferrara, JL, Levine, JE, Reddy, P, Holler, E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61. PubMed PMID: 19282026. Pubmed Central PMCID: 2735047. Epub 2009/03/14. eng.Google Scholar

Vianello, F, Cannella, L, Coe, D, Chai, JG, Golshayan, D, Marelli-Berg, FM, et al. Enhanced and aberrant T cell trafficking following total body irradiation: a gateway to graft-versus-host disease? Br J Haematol. 2013;162(6):808–18. PubMed PMID: 23855835.Google Scholar

Bar, M, Sandmaier, BM, Inamoto, Y, Bruno, B, Hari, P, Chauncey, T, et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant. 2013 19(6):949–57.Google Scholar

Schmid, C, Schleuning, M, Hentrich, M, Markl, GE, Gerbitz, A, Tischer, J, et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant. 2008;41(8):721–7.Google Scholar

Schmid, C, Labopin, M, Nagler, A, Bornhauser, M, Finke, J, Fassas, A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25:4938–45.CrossRefGoogle ScholarPubMed

Campregher, PV, Gooley, T, Scott, BL, Moravec, C, Sandmaier, B, Martin, PJ, et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant. 2007;40(10):965–71.Google Scholar

Elliott, MA, Tefferi, A, Hogan, WJ, Letendre, L, Gastineau, DA, Ansell, SM, et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2006; 37(11):1003–8.Google Scholar

Krishnamurthy, P, Potter, VT, Barber, LD, Kulasekararaj, AG, Lim, ZY, Pearce, RM, de Lavallade, H, et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2013;19(4):562–8.Google Scholar

Liga, M, Triantafyllou, E, Tiniakou, M, Lambropoulou, P, Karakantza, M, Zoumbos, NC, et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biol Blood Marrow Transplant. 2013;19(1):75–81.Google Scholar

Schroeder, T, Fröbel, J, Cadeddu, RP, Czibere, A, Dienst, A, Platzbecker, U, et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia. 2013;27(9):1910–3.Google Scholar

McLornan, DP, Mead, AJ, Jackson, G, Harrison, CN. Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol. 2012;157(4):413–25.Google Scholar

Kröger, N, Alchalby, H, Klyuchnikov, E, Badbaran, A, Hildebrandt, Y, Ayuk, F, et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009;113(8):1866–8.Google Scholar

Yoshimi, A, Bader, P, Matthes-Martin, S, Stary, J, Sedlacek, P, Duffner, U et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia 2005;19:971–7.Google Scholar

El-Jurdi, N, Reljic, T, Kumar, A, Pidala, J, Bazarbachi, A, Djulbegovic, B, et al. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy. 2013;5(5):457–66.Google Scholar

Bloor, AJ, Thomson, K, Chowdhry, N, Verfuerth, S, Ings, SJ, Chakraverty, R, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(1):50–8.Google Scholar

Thomson, KJ, Morris, EC, Milligan, D, Parker, AN, Hunter, AE, Cook, G, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol. 2010;28(23):3695–700.Google Scholar

Peggs, KS, Kayani, I, Edwards, N, Kottaridis, P, Goldstone, AH, Linch, DC et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin’s lymphoma. J Clin Oncol. 2011;29(8):971–8.Google Scholar

Theurich, S, Malcher, J, Wennhold, K, Shimabukuro-Vornhagen, A, Chemnitz, J, Holtick, U, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol. 2013;31(5):e59-63.Google Scholar

Sala, E, Crocchiolo, R, Gandolfi, S, Bruno-Ventre, M, Bramanti, S, Peccatori, J, et al. Bendamustine combined with donor lymphocytes infusion in Hodgkin’s lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(9):1444–7.Google Scholar

Richardson, SE, Khan, I, Rawstron, A, Sudak, J, Edwards, N, Verfuerth, S, et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. Br J Haematol. 2013;160(5):640–8.Google Scholar

Slavin, S, Naparstek, E, Nagler, A, Ackerstein, A, Samuel, S, Kapelushnik, J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87:2195–204.Google Scholar

Collins, RH Jr., Goldstein, S, Giralt, S, Levine, J, Porter, D, Drobyski, W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26:511–16.Google Scholar

Medd, PG, Peniket, AJ, Littlewood, TJ, Pearce, R, Perry, J, Kirkland, KE et al; British Society of Blood and Marrow Transplantation. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. Bone Marrow Transplant. 2013;48(7):982–7.Google Scholar

van de Donk, NW, Kröger, N, Hegenbart, U, Corradini, P, San Miguel, JF, Goldschmidt, H, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2006;37(12):1135–41.Google Scholar

Stern, M, de Wreede, LC, Brand, R, van Biezen, A, Dreger, P, Mohty, M, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia. 2014; Apr 30. [Epub ahead of print]Google Scholar

Tyler, EM, Jungbluth, AA, O’Reilly, RJ, Koehne, G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood. 2013;121(2):308–17.Google Scholar

Cooper, N., Rao, K., Goulden, N., Amrolia, P. and Veys, P. Alpha interferon augments the graft-versus-leukaemia effect of second stem cell transplants and donor lymphocyte infusions in high-risk paediatric leukaemias. Br J Haematol. 2012;156:550–2.Google Scholar

El-Cheikh, J, Crocchiolo, R, Furst, S, Ladaique, P, Castagna, L, Faucher, C, et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol. 2012;40(7):521–7.Google Scholar

Rizzieri, DA, Storms, R, Chen, DF, Long, G, Yang, Y, Nikcevich, DA et al. Natural killer cell-enriched donor lymphocyte infusions from A 3–6/6 HLA-matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(8):1107–14.Google Scholar

Ho, VT, Kim, HT, Kao, G, Cutler, C, Levine, J, Rosenblatt, J, et al. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014; Aug 13. [Epub ahead of print]Google Scholar

Wagner, E, Wehler, D, Kolbe, K, Theobald, M, Herr, W and Meyer, R. Impact of Prophylactic CD8-Depleted Donor-Lymphocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation and Alemtuzumab Mediated T-Cell Depletion. Abstract 4109. American Society of Hematology Annual Meeting 2013.Google Scholar

Samarasinghe, S, Mancao, C, Pule, M, Nawroly, N, Karlsson, H, Brewin, J, et al. Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood. 2010;115(2):396–407.Google Scholar

Solomon, SR, Mielke, S, Savani, BN, Montero, A, Wisch, L, Childs, R, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005;106(3):1123–9. Epub 2005 Apr 7.Google Scholar

Ciceri, F, Bonini, C, Marktel, S, Zappone, E, Servida, P, Bernadi, M et al. Anti-tumor effect of HSV-TK engineered donor lymphocytes after allogeneic stem cell transplantation. Blood. 2007;109:4698–707.Google Scholar

Ciceri, F, Lupo-Stanghellini, M, Oliveira, G, Greco, R et al. Long-term safety and survival outcomes after TK-expressing donor lymphocyte infusion (TK-DLI) in allogeneic hematopoietic stem cell transplantation (HSCT).J Clin Oncol. 2013;31(Suppl): abstr 7007.Google Scholar

Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C, Vago, L, Bondanzo, A et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83.Google Scholar

Gooley, TA, Chien, JW, Pergam, SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.Google Scholar

Horan, JT, Logan, BR, Agovi-Johnson, MA, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29(7):805–13.Google Scholar

Anasetti, C, Logan, BR, Lee, SJ, et al. Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487–96.Google Scholar

Rocha, V, Labopin, M, Sanz, G, et al. Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22):2276–85.Google Scholar

Locatelli, F, Kabbara, N, Ruggeri, A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013;122(6):1072–8.Google Scholar

Bernaudin, F, Socie, G, Kuentz, M, et al. SFGM-T: .Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007;110(7):2749–56.Google Scholar

Porter, DL, Alyea, EP, Antin, JH, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010;16(11):1467–503.Google Scholar

Schmid, C, Labopin, M, Nagler, A, et al. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012;119(6):1599–606.Google Scholar

Pollyea, DA, Artz, AS, Stock, W, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007;40(11):1027–32.Google Scholar

Kenkre, VP, Horowitz, S, Artz, AS, et al. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leuk Lymphoma. 2011;52(2):214–22.Google Scholar

Elmaagacli, AH, Beelen, DW, Schaefer, UW. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20(12):1045–55.Google Scholar

Mehta, J, Powles, R, Kulkarni, S, et al. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant. 1997;20(2):129–35.Google Scholar

Higano, CS, Brixey, M, Bryant, EM, et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation. 1990;50(1):175–7.Google Scholar

Giralt, S, Escudier, S, Kantarjian, H, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 1993;329(11):757–61.Google Scholar

Worth, LL, Mullen, CA, Choroszy, M, et al. Treatment of leukemia relapse with recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) following unrelated umbilical cord blood transplant: Induction of graft-vs.-leukemia. Pediatr Transplant. 2002;6(5):439–42.Google Scholar

Jabbour, E, Giralt, S, Kantarjian, H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009;115(9):1899–905.Google Scholar

Bolaños-Meade, J, Smith, BD, Gore, SD, et al. 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2011;17(5):754–8.Google Scholar

Czibere, A, Bruns, I, Kröger, N, et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant. 2010;45(5):872–6.Google Scholar

Fathi, AT, Chen, YB. Treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Curr Hematol Malig Rep. 2014;9(2):186–92.Google Scholar

Giralt, SA, Champlin, RE. Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994;84(11):3603–12.Google Scholar

Sharma, M, Ravandi, F, Bayraktar, UD, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011;17(12):1874–7.Google Scholar

Metzelder, SK, Schroeder, T, Finck, A, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012;26(11):2353–9.Google Scholar

Kolb, HJ, Mittermüller, J, Clemm, C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462–5.Google Scholar

Kolb, HJ, Schattenberg, A, Goldman, JM, et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–50.Google Scholar

Porter, DL, Collins, RH Jr, Hardy, C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000;95(4):1214–21.Google Scholar

Schmid, C, Labopin, M, Nagler, A, et al. EBMT Acute Leukemia Working Party. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(31):4938–45.Google Scholar

Schroeder, T, Czibere, A, Platzbecker, U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229–35.Google Scholar

Hasskarl, J, Zerweck, A, Wäsch, R, et al. Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft. Bone Marrow Transplant. 2012;47(2):277–82.Google Scholar

Warlick, ED, DeFor, T, Blazar, BR, et al. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):480–6.Google Scholar

Porter, DL, Collins, RH Jr, Shpilberg, O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant. 1999;5(4):253–61.Google Scholar

Fan, Y, Liu, H, Artz, A et al. The outcomes of second allogeneic stem cell transplantation for disease relapse after T cell depleted allogeneic stem cell transplantation: A single center experience, University of Chicago. Blood. 2014;124:2509.Google Scholar

Christopeit, M, Kuss, O, Finke, J, et al. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013;31(26):3259–71.Google Scholar

Leung, AY, Tse, E, Hwang, YY, et al. Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor. Am J Hematol. 2013;88(6):485–91.Google Scholar

Christopoulos, P, Schmoor, C, Waterhouse, M, et al. Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML. Bone Marrow Transplant. 2013;48(7):901–7.Google Scholar

Poon, LM, Bassett, R Jr, Rondon, G, et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013;48(5):666–70.Google Scholar

Spyridonidis, A, Labopin, M, Schmid, C, et al. Immunotherapy Subcommittee of Acute Leukemia Working Party. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26(6):1211–7.Google Scholar

Hartwig, M, Ocheni, S, Asenova, S, et al. Second allogeneic stem cell transplantation in myeloid malignancies. Acta Haematol. 2009;122(4):185–92.Google Scholar

Shaw, BE, Mufti, GJ, Mackinnon, S, et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant. 2008;42(12):783–9.Google Scholar

Eapen, M, Giralt, SA, Horowitz, MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34(8):721–7.Google Scholar

Chueh, HW, Lee, SH, Sung, KW, et al. Second allogeneic stem cell transplantation in hematologic malignancies: a single-center experience. J Pediatr Hematol Oncol. 2013;35(6):424–9.CrossRefGoogle ScholarPubMed

Sorror, ML. Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program. 2010;2010:237–47.Google Scholar

Artz, AS, Pollyea, DA, Kocherginsky, M, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12(9):954–64.Google Scholar

Kishi, K, Takahashi, S, Gondo, H, et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant. 1997;19(5):461–6.Google Scholar

Hill, BT, Bolwell, BJ, Rybicki, L, et al. Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants. Biol Blood Marrow Transplant. 2010;16(12):1738–46.Google Scholar

Kedmi, M, Resnick, IB, Dray, L, et al. A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant. 2009;15(4):483–9.Google Scholar

Wagner, JE, Vogelsang, GB, Zehnbauer, BA, et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant. 1992;9(3):205–9.Google Scholar

Hurley, CK, Raffoux, C; World Marrow Donor Association. World Marrow Donor Association: international standards for unrelated hematopoietic stem cell donor registries. Bone Marrow Transplant. 2004;34(2):103–10.Google Scholar

Barrett, AJ, Locatelli, F, Treleaven, JG, et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol. 1991;79(4):567–74.Google Scholar

Al-Qurashi, F, Ayas, M, Al Sharif, F, et al. Second allogeneic bone marrow transplantation after myeloablative conditioning analysis of 43 cases from single institution. Hematology. 2004;9(2):123–9.Google Scholar

Storb, R, Gyurkocza, B, Storer, BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530–8Google Scholar

Bhatia, S, Francisco, L, Carter, A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784–92.Google Scholar

Bosi, A, Laszlo, D, Labopin, M, et al. Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2001;19(16):3675–84.Google Scholar

Russell, JA, Bowen, T, Brown, C, et al. Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells. Bone Marrow Transplant. 1996;18(3):501–5.Google Scholar

Körbling, M, Huh, YO, Durett, A, et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995;86(7):2842–8.Google Scholar

Stroncek, DF, Lopez, AM, Maharaj, D, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood. 2013;121(1):197–206.Google Scholar

Churpek, JE, Nickels, E, Marquez, R, et al. Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. Blood. 2012;120(26):5247–9.Google Scholar

Srinivasan, R, Takahashi, Y, McCoy, JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006;133(3):305–14.Google Scholar

Champlin, RE, Horowitz, MM, van Bekkum, DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73(2):606–13.Google Scholar

Rondón, G, Saliba, RM, Khouri, I, et al. Long-term follow-up of patients who experienced graft failure post allogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant. 2008;14(8):859–66.Google Scholar

Schriber, J, Agovi, MA, Ho, V, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant. 2010;16(8):1099–106.Google Scholar

Fleischhauer, K, Locatelli, F, Zecca, M, et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood. 2006;107(7):2984–92.Google Scholar

Young, JW, Papadopoulos, EB, Cunningham, I, et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood. 1992;79(12):3380–7.Google Scholar

Anasetti, C, Amos, D, Beatty, PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320(4):197–204.Google Scholar

Ruggeri, A, Labopin, M, Sormani, MP, et al. Engraftment kinetics and graft failure after single umbilical cord blood transplantation using myeloablative conditioning regimen. Haematologica. 2014;99:1509–15.Google Scholar

Ciurea, SO, de Lima, M, Cano, P, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88(8):1019–24.Google Scholar

Cutler, C, Kim, HT, Sun, L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118(25):6691–7.Google Scholar

Laughlin, MJ, Eapen, M, Rubinstein, P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351(22):2265–75.Google Scholar

Lazarus, HM, Kan, F, Tarima, S, et al. Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. Biol Blood Marrow Transplant. 2009;15(5):589–96.Google Scholar

Lioznov, M, Dellbrügger, C, Sputtek, A, et al. Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM. Bone Marrow Transplant. 2008;42(2):121–8.Google Scholar

Ramirez, P, Wagner, JE, DeFor, TE, et al. Factors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant. 2012;47(6):799–803.Google Scholar

Storb, R, Epstein, RB, Rudolph, RH, Thomas, ED. The effect of prior transfusion on marrow grafts between histocompatible canine siblings. J Immunol. 1970;105(3):627–33.Google Scholar

Storb, R, Rudolph, RH, Graham, TC, Thomas, ED. The influence of transfusions from unrelated donors upon marrow grafts between histocompatible canine siblings. J Immunol. 1971;107(2):409–13.Google Scholar

Xu, H, Chilton, PM, Tanner, MK, et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood. 2006;108(10):3611–9.Google Scholar

Taylor, PA, Ehrhardt, MJ, Roforth, MM, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood. 2007;109(3):1307–15.Google Scholar

Takanashi, M, Atsuta, Y, Fujiwara, K, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood. 2010;116(15):2839–46.Google Scholar

Spellman, S, Bray, R, Rosen-Bronson, S, et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood. 2010;115(13):2704–8.Google Scholar

Ruggeri, A, Rocha, V, Masson, E, et al. Impact of donor-specific anti-HLA antibodies on graft failure and survival after reduced intensity conditioning-unrelated cord blood transplantation: a Eurocord, Société Francophone d’Histocompatibilité et d’Immunogénétique (SFHI) and Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) analysis. Haematologica. 2013;98(7):1154–60.Google Scholar

Storb, R. B-cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients. Blood. 2009;113(5):1205.Google Scholar

Brunstein, CG, Noreen, H, DeFor, TE, et al. Anti-HLA antibodies in double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011;17(11):1704–8.Google Scholar

Ferrà, C, Sanz, J, Díaz-Pérez, MA, et al. Outcome of graft failure after allogeneic stem cell transplantation: Study of 89 patients. Leuk Lymphoma. 2014;10:1–24.Google Scholar

Fuji, S, Nakamura, F, Hatanaka, K, et al. Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2012;18(9):1407–14.Google Scholar

Waki, F, Masuoka, K, Fukuda, T, et al. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transplant. 2011;17(6):841–51.Google Scholar

Remberger, M, Mattsson, J, Olsson, R, Ringdén, O. Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. Clin Transplant. 2011;25(1):E68–76.Google Scholar

Byrne, BJ, Horwitz, M, Long, GD, et al. Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. Bone Marrow Transplant. 2008;41(1):39–43.Google Scholar

Jabbour, E, Rondon, G, Anderlini, P, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2007;40(5):431–5.Google Scholar

Chewning, JH, Castro-Malaspina, H, Jakubowski, A, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant. 2007;13(11):1313–23.Google Scholar

Remberger, M, Ringdén, O, Ljungman, P, Hägglund, H, et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998;22(1):73–8.Google Scholar

Appelbaum, FR, Nemunaitis, J, Singer, JW, et al. Use of recombinant human granulocyte macrophage colony-stimulating factor to speed engraftment and treat graft failure following marrow transplantation in man. Haematol Blood Transfus. 1990;33:736–40.Google Scholar

Nemunaitis, J, Singer, JW, Buckner, CD, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood. 1990;76(1):245–53.Google Scholar

Poon, LM, Di Stasi, A, Popat, U, et al. Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation.Am J Blood Res. 2013;3(3):260–4.Google Scholar